TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 29377953

Group type: EXPERIMENTAL
Intervention: Ganciclovir gel, 0.15% 1cc 5 times a day for 6 weeks
Number of subjects: 29
Study: 29378049

Group type: EXPERIMENTAL
Intervention: δ13C biomarker measured using fingerstick blood samples
Number of subjects: 326

Group type: EXPERIMENTAL
Intervention: δ13C biomarker
Number of subjects: 326
Study: 29378056

Group type: EXPERIMENTAL
Intervention: Lysine intake of 36.6 mg·kg-1·d-1 during early gestation
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Lysine intake of 50.3 mg·kg-1·d-1 during late gestation
Number of subjects: 33
Study: 29378526

Group type: EXPERIMENTAL
Intervention: Saving Babies' Lives care bundle
Number of subjects: 100000

Group type: EXPERIMENTAL
Intervention: Cost of implementing the care bundle
Number of subjects: 100000

Group type: EXPERIMENTAL
Intervention: Questionnaires with service users and care providers
Number of subjects: 100000
Study: 29378547

Group type: EXPERIMENTAL
Intervention: Risperidone long-acting injectables (RLAIs) or paliperidone palmitate (PP) long-acting injectables (LAIs)
Number of subjects: 1065

Group type: COMPARATOR
Intervention: Oral antipsychotic treatments (APT)
Number of subjects: 1065

Group type: COMPARATOR
Intervention: Other injectable antipsychotic treatments (APT)
Number of subjects: 1065

Group type: EXPERIMENTAL
Intervention: Long-acting injectables (LAI) APT
Number of subjects: 1065

Group type: COMPARATOR
Intervention: Oral APT
Number of subjects: 1065
Study: 29378563

Group type: EXPERIMENTAL
Intervention: Performance on the four FitnessGram tests (PACER, curl-up, push-up, trunk lift)
Number of subjects: 265

Group type: EXPERIMENTAL
Intervention: Performance on the four FitnessGram tests
Number of subjects: 265

Group type: EXPERIMENTAL
Intervention: Physically fit boys and girls
Number of subjects: 265

Group type: EXPERIMENTAL
Intervention: Physically fit girls
Number of subjects: 265

Group type: EXPERIMENTAL
Intervention: Overall performance on the four physical fitness tests
Number of subjects: 265

Group type: EXPERIMENTAL
Intervention: Performance on the four physical fitness tests
Number of subjects: 265
Study: 29378602

Group type: EXPERIMENTAL
Intervention: Simeprevir plus pegylated interferon-α and ribavirin (PR)
Number of subjects: 249
Study: 29378632

Group type: EXPERIMENTAL
Intervention: 12-week physical activity intervention (60 min, 3 days/week) targeting 10,000 steps per day
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Participants at risk for CVD
Number of subjects: 50
Study: 29378647

Group type: EXPERIMENTAL
Intervention: CR-POSSUM
Number of subjects: 2749

Group type: COMPARATOR
Intervention: POSSUM
Number of subjects: 2749

Group type: COMPARATOR
Intervention: IRCS
Number of subjects: 2749
Study: 29378733

Group type: EXPERIMENTAL
Intervention: Neoadjuvant Carboplatin and Docetaxel
Number of subjects: 0
Study: 29378789

Group type: EXPERIMENTAL
Intervention: Teenage exercise
Number of subjects: 0
Study: 29378790

Group type: EXPERIMENTAL
Intervention: Heterozygous carriers for Gaucher's disease (GD) causing pathogenic mutations
Number of subjects: 1893

Group type: EXPERIMENTAL
Intervention: Non-synonymous variants previously associated with PD
Number of subjects: 1893

Group type: EXPERIMENTAL
Intervention: Variants of unknown significance
Number of subjects: 1893
Study: 29379040

Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging (MRI) of the cervical spinal cord
Number of subjects: 0

Group type: COMPARATOR
Intervention: Non-invasive ventilation
Number of subjects: 0
Study: 29379652

Group type: EXPERIMENTAL
Intervention: Autologous platelet-rich plasma (E-PRP) eye drops, 6 times a day for 6 weeks
Number of subjects: 80
Study: 29380080

Group type: EXPERIMENTAL
Intervention: Maximum respiratory pressures measured through an intubation catheter
Number of subjects: 90

Group type: COMPARATOR
Intervention: Maximum respiratory pressures measured through a standard mouthpiece
Number of subjects: 90
Study: 29380442

Group type: EXPERIMENTAL
Intervention: Locoregional treatment (including Radiofrequency ablation and combination therapy)
Number of subjects: 4978

Group type: EXPERIMENTAL
Intervention: Radiofrequency ablation (RFA)
Number of subjects: 4978

Group type: EXPERIMENTAL
Intervention: Combination of RFA and transarterial chemoembolization
Number of subjects: 4978
Study: 29380445

Group type: EXPERIMENTAL
Intervention: Self-reported non-adherence to immunosuppressive medication
Number of subjects: 504

Group type: EXPERIMENTAL
Intervention: Healthcare worker (HCW) assessment of adherence
Number of subjects: 504

Group type: EXPERIMENTAL
Intervention: Self-reported non-adherence over time
Number of subjects: 504

Group type: EXPERIMENTAL
Intervention: Main reason for non-adherence
Number of subjects: 504

Group type: EXPERIMENTAL
Intervention: Explanations for non-adherence
Number of subjects: 504

Group type: EXPERIMENTAL
Intervention: Medication knowledge and trough levels
Number of subjects: 504
Study: 29380903

Group type: EXPERIMENTAL
Intervention: Iron supplementation
Number of subjects: 0

Group type: COMPARATOR
Intervention: Not available
Number of subjects: 0
Study: 29381090

Group type: EXPERIMENTAL
Intervention: Eversense CGM system
Number of subjects: 90
Study: 29381435

Group type: EXPERIMENTAL
Intervention: Selinexor 80 mg and dexamethasone 20 mg, both orally and twice weekly
Number of subjects: 79
Study: 29381790

Group type: EXPERIMENTAL
Intervention: Healthy Eating Index for pregnant women in Singapore (HEI-SGP)
Number of subjects: 1051
Study: 29381792

Group type: EXPERIMENTAL
Intervention: Childhood cancer survivors (CCSs)
Number of subjects: 2365

Group type: EXPERIMENTAL
Intervention: Leukemia survivors
Number of subjects: 2365

Group type: COMPARATOR
Intervention: Siblings of CCSs
Number of subjects: 2365

Group type: COMPARATOR
Intervention: General population
Number of subjects: 2365

Group type: EXPERIMENTAL
Intervention: CCSs treated with cranial radiotherapy (≥20 Gy)
Number of subjects: 2365
Study: 29381795

Group type: EXPERIMENTAL
Intervention: Elevated PAr (highest quartile)
Number of subjects: 6891
Study: 29381798

Group type: EXPERIMENTAL
Intervention: Ramadan fasting
Number of subjects: 29
Study: 29381826

Group type: EXPERIMENTAL
Intervention: Itraconazole (200 mg twice daily) with osimertinib (80 mg on Days 1 and 10)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Rifampicin (600 mg once daily) with osimertinib (80 mg once daily on Days 1-77)
Number of subjects: 36
Study: 29381834

Group type: EXPERIMENTAL
Intervention: Occupational therapy consisting of thermal modalities, tissue mobilization, and upper extremity mobility exercises, with 8 weekly in-person sessions.
Number of subjects: 21
Study: 29381843

Group type: EXPERIMENTAL
Intervention: Epratuzumab
Number of subjects: 1584

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1584
Study: 29382367

Group type: EXPERIMENTAL
Intervention: A-CHESS for 12 months
Number of subjects: 280

Group type: EXPERIMENTAL
Intervention: Telephone Monitoring and Counseling (TMC) for 12 months
Number of subjects: 280

Group type: EXPERIMENTAL
Intervention: A-CHESS + TMC for 12 months
Number of subjects: 280

Group type: COMPARATOR
Intervention: Standard continuing care
Number of subjects: 280
Study: 29382379

Group type: EXPERIMENTAL
Intervention: Baseline ultrasonography (US) of the hands, wrists, and feet
Number of subjects: 194

Group type: EXPERIMENTAL
Intervention: Baseline DAS28
Number of subjects: 194

Group type: EXPERIMENTAL
Intervention: Presence of rheumatoid factor
Number of subjects: 194

Group type: EXPERIMENTAL
Intervention: Type of monitoring strategy
Number of subjects: 194
Study: 29382394

Group type: EXPERIMENTAL
Intervention: meropenem
Number of subjects: 19
Study: 29382391

Group type: EXPERIMENTAL
Intervention: Combination of lopinavir/ritonavir and recombinant interferon-β1b with standard supportive care
Number of subjects: 13

Group type: COMPARATOR
Intervention: Placebo with standard supportive care
Number of subjects: 13
Study: 29382504

Group type: EXPERIMENTAL
Intervention: Balanced high fat diet (BHFD) for 16 weeks
Number of subjects: 144
Study: 29382510

Group type: EXPERIMENTAL
Intervention: Preoperative Renal Functional Reserve (RFR) measured by high oral protein load test
Number of subjects: 110

Group type: EXPERIMENTAL
Intervention: Risk prediction model including demographic and comorbidity covariates, RFR, and intraoperative variables
Number of subjects: 110

Group type: EXPERIMENTAL
Intervention: Postoperative cell cycle arrest markers at various times
Number of subjects: 110
Study: 29382631

Group type: EXPERIMENTAL
Intervention: Thalamic stimulation (Vim/DRT)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Subthalamic nucleus (STN) stimulation
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Combined stimulation of Vim/DRT and STN
Number of subjects: 18
Study: 29382679

Group type: EXPERIMENTAL
Intervention: Pulse oximetry
Number of subjects: 49
Study: 29382747

Group type: EXPERIMENTAL
Intervention: JAK2 inhibition
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 29382815

Group type: EXPERIMENTAL
Intervention: Sustained anticipation of electric shock
Number of subjects: 0
Study: 29382957

Group type: EXPERIMENTAL
Intervention: Citalopram treatment (level 1 treatment)
Number of subjects: 2280
Study: 29383572

Group type: EXPERIMENTAL
Intervention: Lisdexamfetamine dimesylate (30, 50 or 70 mg/day) for 104 weeks
Number of subjects: 314
Study: 29383680

Group type: EXPERIMENTAL
Intervention: Emergency surgery
Number of subjects: 0
Study: 29383782

Group type: EXPERIMENTAL
Intervention: Inhaled corticosteroids (ICS) completely withdrawn
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Inhaled corticosteroids (ICS) stepped-down to a reduced dose
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Baseline predictors of failure to stop ICS
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: After first step-down of ICS
Number of subjects: 36
Study: 29384473

Group type: EXPERIMENTAL
Intervention: Task-related processes
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Combination of MEG and fMRI data
Number of subjects: 0
Study: 29384721

Group type: EXPERIMENTAL
Intervention: Systemic staging imaging within 30 days of locoregional recurrence
Number of subjects: 445

Group type: EXPERIMENTAL
Intervention: Locoregional recurrence types (lymph node, postmastectomy chest wall, in-breast)
Number of subjects: 445

Group type: EXPERIMENTAL
Intervention: Initial presenting stage
Number of subjects: 445

Group type: EXPERIMENTAL
Intervention: Locoregional recurrence type
Number of subjects: 445

Group type: EXPERIMENTAL
Intervention: Insurance status
Number of subjects: 445
Study: 29384927

Group type: EXPERIMENTAL
Intervention: Micafungin
Number of subjects: 68
Study: 29385166

Group type: EXPERIMENTAL
Intervention: Locomotor training (LT) on a treadmill using body-weight support for 80 daily one-hour sessions
Number of subjects: 8

Group type: COMPARATOR
Intervention: Usual care (non-trained; regular at-home routine)
Number of subjects: 8
Study: 29385370

Group type: EXPERIMENTAL
Intervention: Tisagenlecleucel
Number of subjects: 75
Study: 29385376

Group type: EXPERIMENTAL
Intervention: 19-28z CAR T cells infusion
Number of subjects: 53
Study: 29385399

Group type: EXPERIMENTAL
Intervention: Low-sodium intervention (51.3 mmol sodium/day)
Number of subjects: 99

Group type: EXPERIMENTAL
Intervention: High-sodium intervention (307.8 mmol sodium/day)
Number of subjects: 99

Group type: EXPERIMENTAL
Intervention: High-sodium with potassium supplementation (60.0 mmol potassium/day)
Number of subjects: 99
Study: 29385444

Group type: EXPERIMENTAL
Intervention: Oral doxycycline (100 mg q12h)
Number of subjects: 200

Group type: COMPARATOR
Intervention: Intravenous ceftriaxone (2 g q24h)
Number of subjects: 200

Group type: COMPARATOR
Intervention: Control group (192 subjects without history of Lyme borreliosis)
Number of subjects: 200
Study: 29385837

Group type: EXPERIMENTAL
Intervention: Plasma biomarker protein panel consisting of 16 proteins
Number of subjects: 545

Group type: EXPERIMENTAL
Intervention: L-selectin
Number of subjects: 545

Group type: EXPERIMENTAL
Intervention: Insulin-like growth factor-binding protein 3
Number of subjects: 545

Group type: EXPERIMENTAL
Intervention: Coagulation factor X
Number of subjects: 545

Group type: EXPERIMENTAL
Intervention: Serum paraoxonase/lactonase 3
Number of subjects: 545

Group type: EXPERIMENTAL
Intervention: Thrombospondin-1
Number of subjects: 545

Group type: EXPERIMENTAL
Intervention: Hyaluronan-binding protein 2
Number of subjects: 545

Group type: EXPERIMENTAL
Intervention: Heparin cofactor 2
Number of subjects: 545

Group type: EXPERIMENTAL
Intervention: Apolipoprotein B-100
Number of subjects: 545

Group type: EXPERIMENTAL
Intervention: von Willebrand factor
Number of subjects: 545
Study: 29386048

Group type: EXPERIMENTAL
Intervention: PEEP changes (5 and 10 cmH2O)
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: P-V curve method
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Electrical impedance tomography (EIT)
Number of subjects: 14
Study: 29386196

Group type: EXPERIMENTAL
Intervention: Ibrutinib in combination with R-ICE (rituximab, ifosfamide, carboplatin, etoposide) at 840 mg daily
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Ibrutinib in combination with R-ICE
Number of subjects: 21
Study: 29386195

Group type: EXPERIMENTAL
Intervention: Galinpepimut-S (multivalent WT1 peptide vaccine) administered as 6 vaccinations over 10 weeks, with potential for 6 additional monthly doses if in CR1.
Number of subjects: 0
Study: 29386249

Group type: EXPERIMENTAL
Intervention: DPP-4 inhibitor therapy
Number of subjects: 0
Study: 29386274

Group type: EXPERIMENTAL
Intervention: BEEMS (Balance and Eye-Movement Exercises)
Number of subjects: 88

Group type: COMPARATOR
Intervention: Control (no treatment)
Number of subjects: 88
Study: 29386298

Group type: EXPERIMENTAL
Intervention: Bacterial and eosinophilic exacerbations
Number of subjects: 101

Group type: COMPARATOR
Intervention: Viral exacerbations
Number of subjects: 101

Group type: EXPERIMENTAL
Intervention: COPD phenotypes
Number of subjects: 101
Study: 29386411

Group type: EXPERIMENTAL
Intervention: Vitamin D supplementation
Number of subjects: 0
Study: 29386888

Group type: EXPERIMENTAL
Intervention: Fluticasone furoate-vilanterol
Number of subjects: 229

Group type: COMPARATOR
Intervention: Vilanterol alone
Number of subjects: 229
Study: 29386912

Group type: COMPARATOR
Intervention: Subcutaneous tanezumab (2.5, 5, and 10 mg)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Subcutaneous tanezumab (2.5 mg)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Subcutaneous tanezumab (5 mg)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Subcutaneous tanezumab (10 mg)
Number of subjects: 0
Study: 29387020

Group type: EXPERIMENTAL
Intervention: Attachment-Based Compassion Therapy (ABCT) combined with treatment as usual (TAU)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Relaxation (active control group) combined with treatment as usual (TAU)
Number of subjects: 42
Study: 29387022

Group type: EXPERIMENTAL
Intervention: Magnetic Seizure Therapy (MST)
Number of subjects: 8
Study: 29387432

Group type: EXPERIMENTAL
Intervention: Higher baseline suPAR levels
Number of subjects: 411

Group type: EXPERIMENTAL
Intervention: Higher baseline suPAR levels (adjusted for risk score)
Number of subjects: 411
Study: 29387473

Group type: EXPERIMENTAL
Intervention: H5VLP vaccine co-administered with Alhydrogel
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: H5VLP vaccine co-administered with GLA-SE
Number of subjects: 0
Study: 29387681

Group type: EXPERIMENTAL
Intervention: Direct-instruction movement and preliteracy program
Number of subjects: 11
Study: 29387682

Group type: EXPERIMENTAL
Intervention: Ride-on car training combined with an adult-directed social interaction program
Number of subjects: 29

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 29
Study: 29388048

Group type: EXPERIMENTAL
Intervention: DrotAA (drotrecogin alfa)
Number of subjects: 2627

Group type: COMPARATOR
Intervention: Control (nonDrotAA)
Number of subjects: 2627
Study: 29388068

Group type: EXPERIMENTAL
Intervention: NSF patients
Number of subjects: 28

Group type: COMPARATOR
Intervention: ISF patients
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: ISF patients with narrow-QRS complexes
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: NSF and wide-QRS ISF patients
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Narrow-QRS ISF patients
Number of subjects: 28
Study: 29388336

Group type: EXPERIMENTAL
Intervention: Transdermal oestradiol
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 29388385

Group type: EXPERIMENTAL
Intervention: Weight Watchers (WW)
Number of subjects: 130

Group type: COMPARATOR
Intervention: Self-guided control group (SG)
Number of subjects: 130

Group type: EXPERIMENTAL
Intervention: Both WW and SG
Number of subjects: 130
Study: 29388903

Group type: EXPERIMENTAL
Intervention: FGln tracer (mean, 244 MBq ± 118, <100 μg) administered intravenously
Number of subjects: 25
Study: 29389078

Group type: EXPERIMENTAL
Intervention: 2% Tapinarof cream
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: 1% Tapinarof cream
Number of subjects: 11
Study: 29389157

Group type: EXPERIMENTAL
Intervention: Lifestyle intervention with social ties
Number of subjects: 0
Study: 29389360

Group type: EXPERIMENTAL
Intervention: hESC-derived cardiovascular progenitors (median dose 8.2 million)
Number of subjects: 6
Study: 29389364

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 29389444

Group type: EXPERIMENTAL
Intervention: Pantoprazole, ~1.2 mg/kg lean body weight (LBW)
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Pantoprazole, LBW dosing
Number of subjects: 41
Study: 29390148

Group type: EXPERIMENTAL
Intervention: Mediterranean diet (MedDiet) adherence (MedDietScore)
Number of subjects: 244
Study: 29391051

Group type: EXPERIMENTAL
Intervention: 5 days of high-dose amoxicillin
Number of subjects: 270

Group type: COMPARATOR
Intervention: 10 days of high-dose amoxicillin (reference standard)
Number of subjects: 270
Study: 29391341

Group type: EXPERIMENTAL
Intervention: Unengaged group (n=102)
Number of subjects: 215

Group type: EXPERIMENTAL
Intervention: MVPA evening peak group (n=108)
Number of subjects: 215
Study: 29391374

Group type: EXPERIMENTAL
Intervention: wP (whole-cell pertussis) vaccine as the first vaccine dose
Number of subjects: 500

Group type: COMPARATOR
Intervention: aP (subunit acellular pertussis) vaccine as the first vaccine dose
Number of subjects: 500
Study: 29391382

Group type: EXPERIMENTAL
Intervention: bDMARD treatment
Number of subjects: 3000

Group type: EXPERIMENTAL
Intervention: Diagnostic, prognostic and predictive biomarkers
Number of subjects: 3000
Study: 29391819

Group type: EXPERIMENTAL
Intervention: High flow rate (HFR) at 10.4 mL/s
Number of subjects: 132

Group type: COMPARATOR
Intervention: Low flow rate (LFR) at 1.7 mL/s
Number of subjects: 132

Group type: EXPERIMENTAL
Intervention: High flow rate (HFR)
Number of subjects: 132

Group type: COMPARATOR
Intervention: Low flow rate (LFR)
Number of subjects: 132
Study: 29392234

Group type: EXPERIMENTAL
Intervention: Bupivacaine lozenges (25 mg) taken up to every 2 hours for 7 days plus standard pain treatment minus topical lidocaine
Number of subjects: 50

Group type: COMPARATOR
Intervention: Standard pain treatment including topical lidocaine
Number of subjects: 50
Study: 29392425

Group type: EXPERIMENTAL
Intervention: Plerixafor plus FLAG-Ida regimen
Number of subjects: 57
Study: 29392418

Group type: EXPERIMENTAL
Intervention: N-acetyl-L-cysteine (NAC) supplementation (1 g/day)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Usual diet (UD)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Acute methionine loading (MetLo) (0.1 g Met/kg mass weight)
Number of subjects: 32
Study: 29392450

Group type: EXPERIMENTAL
Intervention: Intravenous artesunate (IV AS) at a maximum tolerated dose (MTD) of 18 mg/kg
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Intravenous artesunate (IV AS) at dosages of 12 mg/kg, 18 mg/kg, and 25 mg/kg
Number of subjects: 19
Study: 29392736

Group type: EXPERIMENTAL
Intervention: Nutrition Quality Improvement Program (QIP)
Number of subjects: 2588

Group type: COMPARATOR
Intervention: Historical controls (medical patients)
Number of subjects: 2588
Study: 29393183

Group type: EXPERIMENTAL
Intervention: Chemotherapy (PCV or temozolomide)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Irradiation alone
Number of subjects: 0
Study: 29393219

Group type: EXPERIMENTAL
Intervention: Ultra-low contrast volume technique for coronary procedures
Number of subjects: 30
Study: 29393655

Group type: EXPERIMENTAL
Intervention: 3HP (isoniazid 900 mg + rifapentine 900 mg)
Number of subjects: 126

Group type: COMPARATOR
Intervention: 9H (isoniazid 300 mg)
Number of subjects: 126

Group type: EXPERIMENTAL
Intervention: Overall (3HP and 9H)
Number of subjects: 126
Study: 29393720

Group type: EXPERIMENTAL
Intervention: Bronchial-challenge-testing (BCT)
Number of subjects: 724

Group type: EXPERIMENTAL
Intervention: BCT in group A
Number of subjects: 724

Group type: EXPERIMENTAL
Intervention: BCT in group B
Number of subjects: 724
Study: 29393986

Group type: EXPERIMENTAL
Intervention: Rituximab-bendamustine (chemoimmunotherapy)
Number of subjects: 681
Study: 29394124

Group type: EXPERIMENTAL
Intervention: Pomalidomide plus low-dose dexamethasone (LoDEX)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 29394125

Group type: EXPERIMENTAL
Intervention: Nivolumab (anti-PD-1)
Number of subjects: 0
Study: 29394251

Group type: EXPERIMENTAL
Intervention: Floatation-REST (1-hour session)
Number of subjects: 50
Study: 29394504

Group type: EXPERIMENTAL
Intervention: Rivaroxaban
Number of subjects: 241

Group type: COMPARATOR
Intervention: INR thresholds
Number of subjects: 241
Study: 29394884

Group type: EXPERIMENTAL
Intervention: Tai Chi intervention (IG, n = 80), 2 lessons per week for 16 weeks, 1 hour per lesson
Number of subjects: 160

Group type: COMPARATOR
Intervention: Control group (CG, n = 80), no treatment, usual recreational activities
Number of subjects: 160
Study: 29394904

Group type: EXPERIMENTAL
Intervention: ORIF with additional wrist arthroscopy
Number of subjects: 50

Group type: COMPARATOR
Intervention: Conventional fluoroscopic-assisted ORIF
Number of subjects: 50
Study: 29394907

Group type: EXPERIMENTAL
Intervention: Protective ventilation strategy (VT set at 6-8 ml/kg, PEEP at 6-8 cmH2O)
Number of subjects: 334

Group type: COMPARATOR
Intervention: Control group (VT set at 10-12 ml/kg, no PEEP or recruitment maneuvers)
Number of subjects: 334
Study: 29394908

Group type: EXPERIMENTAL
Intervention: daily calorie restriction (reduce habitual daily energy intake by 25%)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: intermittent fasting with calorie restriction (alternate between 24-hour periods of fasting and feeding to 150% of habitual daily energy intake)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: intermittent fasting without calorie restriction (alternate between 24-hour periods of fasting and feeding to 200% of habitual daily energy intake)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Current nutritional interventions for weight management
Number of subjects: 60